The information in this section is intended for visitors outside the United States.
More than 500 million people worldwide are living with chronic hepatitis B or C infection, making viral hepatitis many times more common than HIV. Chronic infection with the hepatitis B or C viruses can lead to serious and life-threatening liver damage, including liver cirrhosis (scarring), liver cancer and the need for liver transplantation.
Gilead has developed today’s leading medicines for viral hepatitis.
Sovaldi® (sofosbuvir), given in combination with ribavirin with or without pegylated interferon (depending on the viral genotype), is recommended by the World Health Organization for the treatment of chronic hepatitis C infection. Gilead is working with regional partners to introduce branded Sovaldi in low- and middle-income countries, prioritizing those with the greatest disease burden. The company works with generic drug manufacturers in India to produce high-quality, low-cost generic Sovaldi for use in 91 developing countries.
Viread® (tenofovir disoproxil fumarate) is indicated for the treatment of chronic hepatitis B. We work with regional business partners and generic licensing partners to sell Viread for HBV at discounted prices in more than 125 developing countries. We are working to increase the number of access countries in which Viread is registered for HBV.